The bill caps the price of the co-pay, but the actual cost is still passed on to the consumer through insurance premiums. Meanwhile, the California government has contracted out with a nonprofit pharmaceutical company to manufacture insulin and sell it at cost, which comes out to $30.
This is—in theory at least—more effective, since it forces pharmaceutical companies to compete on price. And if they don't, Californians still have access to a source of cheap insulin.